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Purpose: To directly compare magnetic resonance (MR) imaging and com-
puted tomography (CT) parametric response map (PRM) measure-
ments of gas trapping and emphysema in ex-smokers both with 
and without chronic obstructive pulmonary disease (COPD).
Materials and 
Methods:
Participants provided written informed consent to a protocol that 
was approved by a local research ethics board and Health Canada 
and was compliant with the HIPAA (Institutional Review Board 
Reg. #00000940). The prospectively planned study was performed 
from March 2014 to December 2014 and included 58 ex-smokers 
(mean age, 73 years 6 9) with (n = 32; mean age, 74 years 6 7) 
and without (n = 26; mean age, 70 years 6 11) COPD. MR imaging 
(at functional residual capacity plus 1 L), CT (at full inspiration and 
expiration), and spirometry or plethysmography were performed 
during a 2-hour visit to generate ventilation defect percent (VDP), 
apparent diffusion coefficient (ADC), and PRM gas trapping and 
emphysema measurements. The relationships between pulmo-
nary function and imaging measurements were determined with 
analysis of variance (ANOVA), Holm-Bonferroni corrected Pear-
son correlations, multivariate regression modeling, and the spatial 
overlap coefficient (SOC).
Results: VDP, ADC, and PRM gas trapping and emphysema (ANOVA, P , 
.001) measurements were significantly different in healthy ex-smokers 
than they were in ex-smokers with COPD. In all ex-smokers, VDP 
was correlated with PRM gas trapping (r = 0.58, P , .001) and with 
PRM emphysema (r = 0.68, P , .001). VDP was also significantly 
correlated with PRM in ex-smokers with COPD (gas trapping: r = 
0.47 and P = .03; emphysema: r = 0.62 and P , .001) but not in 
healthy ex-smokers. In a multivariate model that predicted PRM gas 
trapping, the forced expiratory volume in 1 second normalized to the 
forced vital capacity (standardized coefficients [bS] = 20.69, P = .001) 
and airway wall area percent (bS = 20.22, P = .02) were significant 
predictors. PRM emphysema was predicted by the diffusing capacity 
for carbon monoxide (bS = 20.29, P = .03) and VDP (bS = 0.41, P = 
.001). Helium 3 ADC values were significantly elevated in PRM gas-
trapping regions (P , .001). The spatial relationship for ventilation 
defects was significantly greater with PRM gas trapping than with 
PRM emphysema in patients with mild (for gas trapping, SOC = 36% 
6 28; for emphysema, SOC = 1% 6 2; P = .001) and moderate (for 
gas trapping, SOC = 34% 6 28; for emphysema, SOC = 7% 6 15; P = 
.006) COPD. For severe COPD, the spatial relationship for ventilation 
defects with PRM emphysema (SOC = 64% 6 30) was significantly 
greater than that for PRM gas trapping (SOC = 36% 6 18; P = .01).
Conclusion: In all ex-smokers, ADC values were significantly elevated in re-
gions of PRM gas trapping, and VDP was quantitatively and spa-
tially related to both PRM gas trapping and PRM emphysema. In 
patients with mild to moderate COPD, VDP was related to PRM 
gas trapping, whereas in patients with severe COPD, VDP corre-
lated with both PRM gas trapping and PRM emphysema.
q RSNA, 2016
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used to differentiate among current 
and former smokers with and without 
COPD, but the clinical relevance and 
cause of PRM measurements of airways 
disease is uncertain (13).
Single photon emission computed 
tomography and positron emission to-
mography have also been used to depict 
pulmonary function abnormalities in pa-
tients with COPD (14,15). In addition, 
hyperpolarized inhaled noble gas MR im-
aging with helium 3 (3He) and xenon 129 
gases, as well as oxygen-enhanced and 
fluorine 19 magnetic resonance (MR) 
imaging, provide other ways to quantify 
both functional and structural pulmo-
nary biomarkers of COPD (16–19). Hy-
perpolarized 3He MR imaging apparent 
diffusion coefficients (ADCs) reflect the 
size of the lung acinar units. Such values 
are abnormally elevated in smokers with 
and without COPD (20,21). 3He MR im-
aging ventilation defects may reflect both 
airways disease and emphysema in pa-
tients with advanced COPD, but in mild 
COPD and asthma, ventilation defects 
reflect airways disease (22,23). Despite 
the potential of 3He MR imaging, limited 
Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation 
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Advances in Knowledge
 n In 58 ex-smokers with (n = 32) 
and without (n = 26) chronic ob-
structive pulmonary disease 
(COPD), 3He MR imaging ventila-
tion defect percent (VDP) was 
significantly correlated with inspi-
ratory and expiratory CT paramet-
ric response map (PRM) measure-
ments of gas trapping (r = 0.58, P 
, .001) and emphysema (r = 0.68, 
P , .001); 3He apparent diffusion 
coefficient (ADC) values were also 
significantly correlated with PRM 
gas trapping (r = 0.55, P , .001) 
and PRM emphysema (r = 0.62, P 
, .001).
 n In a significant multivariate model 
that predicted PRM gas trapping, 
the forced expiratory volume in 1 
second normalized to the forced 
vital capacity (standardized coeffi-
cient [bS] = 20.69, P = .001) and 
airway wall area percent (bS = 
20.22, P = .02) were significant 
predictors, whereas PRM emphy-
sema was predicted by MR im-
aging VDP (bS = 0.41, P = .001) 
and diffusing capacity for carbon 
monoxide (bS = 20.29, P = .03).
 n In all ex-smokers, spatial CT and 
MR imaging relationships showed 
that 3He MR imaging ADC values 
were significantly elevated in regions 
of PRM gas trapping (P , .001).
 n In patients with mild (for gas trap-
ping, spatial overlap coefficient 
[SOC] = 36% 6 28; for emphy-
sema, SOC = 1% 6 2; P = .001) 
and moderate (for gas trapping, 
SOC = 34% 6 28; for emphy-
sema, SOC = 7% 6 15; P = .006) 
COPD (n = 25), 3He MR imaging 
ventilation defects were quantita-
tively and spatially related to PRM 
gas trapping, whereas in patients 
with severe COPD (n = 7), MR 
imaging ventilation defects were 
quantitatively and spatially related 
to both PRM gas trapping and 
emphysema (for gas trapping, 
SOC = 36% 6 18; for emphy-
sema, SOC = 64% 6 30; P = .01).
Implications for Patient Care
 n In ex-smokers with mild (P = 
.001) and moderate (P = .006) 
COPD, regions of PRM gas trap-
ping were spatially and quantita-
tively related to MR imaging ven-
tilation abnormalities, whereas in 
patients with severe COPD, ven-
tilation abnormalities were re-
lated to both PRM gas trapping 
(P = .009) and PRM emphysema 
(P = .01).
 n While 3He MR imaging is unlikely 
to be translated clinically, this 
information may be used to help 
better understand PRM gas trap-
ping measurements, which may 
be more widely adopted for clin-
ical phenotyping in patients with 
COPD.
related to airway remodeling, inflamma-
tion, and emphysematous destruction 
(1). These pathophysiologic features can 
be regionally quantified by using high-
resolution x-ray computed tomography 
(CT) measurements of the airways and 
parenchyma (2–5). For example, air-
ways disease can be estimated by using 
CT measurements of airway wall area 
percent and lumen area, whereas em-
physema may be estimated by using CT 
attenuation thresholds, such as 2950 
HU or the 15th percentile value from 
inspiratory CT (4,6). The expiratory 
CT attenuation-histogram threshold of 
–856 HU also provides a way to estimate 
gas trapping, reflecting the longer time 
constants for emptying the parenchyma 
via obstructed airways (7).
Recently, parametric response 
mapping (PRM) was used to evaluate 
COPD, breast cancer treatment re-
sponse, and osteoporosis (8–11). In pa-
tients with COPD, coregistered inspi-
ratory and expiratory thoracic CT can 
be evaluated by using well-established 
attenuation thresholds, resulting in 
the classification of healthy, emphyse-
matous, and gas-trapping lung regions 
(9,12). However, the relationship of 
PRM-classified tissue with other estab-
lished measurements of airways disease 
and emphysema is not well understood. 
Very recently, PRM phenotyping was 
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NRPB-SR250, and our manufacturer 
settings were used to calculate total 
effective dose (1.8 mSv for inspiration 
and 1.4 mSv for expiration). For inspi-
ration CT, size-specific dose estimate 
was calculated to be 5–9 mGy on the 
basis of volumetric CT dose index of 4.4 
mGy, total effective dose of 1.8 mSv, 
and size-dependent conversion factor of 
1.00–2.00, an approach used by Chris-
tener et al (26,27). For expiration CT, 
the size-specific dose estimate was 3–7 
mGy on the basis of volumetric CT dose 
index of 3.3 mGy, total effective dose 
of 1.4 mSv, and size-dependent conver-
sion factor of 1.00–2.00.
MR Image Analysis
As was previously described, 3He MR 
imaging semiautomated segmentation 
was performed by a single observer 
(D.P., with 3 years of experience) to 
generate ventilation defect percent 
(VDP), with the ventilation defect vol-
ume normalized to 1H MR imaging tho-
racic cavity volume (28). A detailed de-
scription of this process is provided in 
Appendix E1(online).
CT Image Analysis
CT images were analyzed with Pulmo-
nary Workstation 2.0 (VIDA Diagnos-
tics, Coralville, IA) by a single observer 
(D.P.I.C.,with 2 years of experience) 
to measure wall area percent and seg-
ment the lung regions. These analyses 
are fully automated, as was previously 
described and validated (29,30). The 
relative area of the CT attenuation his-
togram of less than 2950 HU and 2856 
HU at inspiratory and expiratory CT, 
respectively, were determined by using 
MATLAB (Mathworks, Natick, Mass).
Briefly, pulmonary PRM results can 
be generated by coregistering inspi-
ratory and expiratory CT images and 
classifying voxels on the basis of their 
specific thresholds into healthy, gas-
trapping, or emphysema tissue compo-
nents. The specific details of this process 
are given in Appendix E1 (online).
Statistics
Analysis of variance was performed 
with post hoc analysis and Tukey cor-
rection to determine differences in 
(zero padded to 128 3 128); partial-
echo percent, 62.5%; bandwidth, 62.50 
kHz; one excitation; 14 sections; sec-
tion thickness, 15 mm; zero gap.
3He static ventilation MR images 
were acquired by using a fast spoiled 
gradient-recalled-echo method with a 
partial echo and the following param-
eters: total acquisition time, 10 sec; 
3.8/1.0; flip angle, 7°; field of view, 
40 3 40 cm; matrix, 128 3 80 (zero-
padded to 128 3 128); partial-echo 
percent, 62.5%; bandwidth, 62.50 
kHz; one excitation; 14 sections; sec-
tion thickness, 15 mm; zero gap. 3He 
diffusion-weighted MR images were 
also acquired by using fast spoiled gra-
dient-recalled-echo sequence with cen-
tric k-space sampling and the following 
parameters: total acquisition time, 14 
sec; 6.8/4.5; flip angle, 8°; field of view, 
40 3 40 cm; matrix, 128 3 128; band-
width, 62.50 kHz; one excitation; seven 
sections; section thickness, 30 mm; 
zero gap. Two interleaved images were 
also acquired, both with and without 
additional diffusion sensitization and 
the following parameters: 1.94 G/cm; 
b = 1.6 sec/cm2; rise and fall time, 0.5 
msec; gradient duration, 0.46 msec; 
diffusion time, 1.46 msec.
CT Imaging
As was previously described, CT im-
ages were acquired with subjects in the 
supine position approximately 10 mi-
nutes before MR imaging and 1 hour 
after administration of salbutamol. A 
64-section Lightspeed VCT imager (GE 
Healthcare, Milwaukee, Wis) was used 
to acquire breath-hold images at full 
inspiration and full expiration by using 
a spiral acquisition approach and the 
following parameters: detector configu-
ration, 64 3 0.625 mm; peak voltage, 
120 kVp; effective current, 100 mA; ro-
tation time, 500 msec; pitch, 1.0; sec-
tion thickness, 1.25 mm; number of sec-
tions, 200–250, depending on patient 
size; matrix, 512 3 512 (25). CT data 
were reconstructed by using a standard 
convolution kernel to 1.25 mm. The Im-
PACT CT patient dosimetry calculator 
(http://www.impactscan.org/ctdosim-
etry.htm), which is based on the Unit-
ed Kingdom Health Protection Agency 
and unpredictable global quantities and 
high cost have hampered clinical transla-
tion. We wanted to determine the quan-
titative and spatial relationships of PRM 
gas trapping and PRM emphysema mea-
surements with MR imaging measure-
ments of parenchymal tissue integrity 
(ie, ADC) and ventilation because these 
are clinically important imaging findings 
and phenotypes of COPD. Thus, our ob-
jective was to directly compare MR im-
aging and CT PRM measurements of gas 
trapping and emphysema in ex-smokers 
with and without COPD.
Materials and Methods
Study Volunteers
Participants provided written informed 
consent to a protocol that was approved 
by a local research ethics board and 
Health Canada and that was compliant 
with the Health Insurance Portability and 
Accountability Act (Institutional Review 
Board Reg.#00000940). The study was 
prospectively planned and performed 
from March 2014 to December 2014.
MR Imaging
Acquisition of conventional proton (hy-
drogen 1 [1H]), 3He static ventilation, 
and 3He diffusion-weighted MR images 
was performed with a whole-body 3-T 
Discovery MR750 system (GE Health-
care, Milwaukee, Wis), as was previ-
ously described (24). Polarization (Po-
larean; HeliSpin, Durham, NC) was 
achieved to 40%, and the magnetized 
gas was diluted with medical-grade ni-
trogen 2 (N2) gas to a level of 5 mL per 
kilogram of body weight. Coronal im-
ages (multisection, with no gaps) were 
acquired with breath holding from 
functional residual capacity after sub-
jects inhaled a 1-L gas mixture (helium 
4 and N2 for 
1H MR imaging and 3He 
and N2 for 
3He MR imaging). Hydro-
gen 1 MR imaging was performed with 
a whole-body radiofrequency coil and 
a fast spoiled gradient-recalled-echo 
sequence with a partial echo and the 
following parameters: total acquisition 
time, 12 sec; repetition time msec/echo 
time msec, 4.3/1.0; flip angle, 30°; field 
of view, 40 3 40 cm; matrix, 128 3 80 
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of PRM voxels were present, findings re-
flective of normal or healthy tissue.
Ventilation and PRM Measurements by 
GOLD Severity
Table 2 summarizes the measurements 
for MR imaging ventilation and emphy-
sema and for CT-derived gas trapping, 
emphysema, and PRM measurements. In 
ex-smokers with COPD, VDP (P , .001), 
ADC (P , .001), relative area of the CT 
attenuation histogram of less than 2950 
HU (P , .001), PRM gas trapping (P , 
.001), and emphysema (P , .001) were 
significantly greater than in ex-smokers 
with no airflow limitation. There were no 
significant differences in CT airway mea-
surement of wall area percent (P = .9). 
Figure 2 shows that VDP was significantly 
different between healthy ex-smokers 
(8% 6 4) and ex-smokers with moder-
ate (GOLD II, 20% 6 11, P , .001) to 
severe (GOLD III/IV, 37% 6 9, P , .001) 
COPD, but not in ex-smokers with mild 
COPD (GOLD I, 11% 6 6, P = .5). VDP 
was also significantly different between 
those with GOLD I and GOLD II disease 
(P = .04), those with GOLD II and GOLD 
II/IV disease (P , .001), and those with 
GOLD I and GOLD III/IV disease (P , 
.001). PRM measurements were signifi-
cantly different for healthy ex-smokers 
body mass index (P , .001), smoking 
history (pack-years, P = .01), forced 
expiratory volume in 1 second (FEV1, 
P , .001), FEV1 normalized to the 
forced vital capacity (FEV1/FVC, P , 
.001), and diffusing capacity for car-
bon monoxide (DLCO, P , .001), but 
not age (P = .1).
Qualitative Ventilation and PRM Results
Figure 1 shows MR and CT images in 
a representative ex-smoker with no air-
flow limitation and three ex-smokers 
with COPD. In the two ex-smokers with 
more advanced COPD (an 84-year-old 
man with Global Initiative for Chronic 
Obstructive Lung Disease [GOLD] grade 
II; FEV1, 52% of predicted value; FEV1/
FVC, 44%; and a 67-year-old woman 
with GOLD III disease; FEV1, 33% 
of predicted value; FEV1/FVC, 39%), 
more pronounced 3He ventilation de-
fects; a greater number of PRM voxels, 
a finding reflective of emphysema; and 
elevated ADC values were present. Al-
ternatively, in two ex-smokers with mild 
or no disease (a 55-year-old man with 
FEV1, 83% of predicted value and FEV1/
FVC, 77% and a 69-year-old man with 
GOLD I disease; FEV1, 89% of predicted 
value; FEV1/FVC, 69%), more homoge-
neous ventilation and a greater number 
participant characteristics and imaging 
measurements by using SPSS Statistics 
V22.0 (SPSS, Chicago, Ill). Pearson 
correlation coefficients were deter-
mined for MR imaging, and PRM mea-
surements were adjusted with Holm-
Bonferroni correction. The agreement 
between CT PRM and 3He MR imaging 
measurements was evaluated with the 
Bland-Altman method and GraphPad 
Prism V6.0 (GraphPad Software, La 
Jolla, Calif). Multivariate regression 
models for both PRM gas trapping and 
PRM emphysema were determined 
with the step-wise method; variables 
were added to the model when P , .15 
and removed when P  .15 by using 
SPSS software.
Results
Participant Characteristics
Table 1 shows demographic charac-
teristics and pulmonary function mea-
surements for 58 participants (mean 
age, 73 years 6 9), including 26 ex-
smokers with normal spirometry re-
sults (mean age, 70 years 6 11) and 
32 ex-smokers with COPD (mean age, 
74 years 6 7). Patient subgroups were 
significantly different with respect to 
Table 1
Subject Demographics
Characteristic
Healthy 
Ex-Smokers 
(n = 26)
Ex-smokers with COPD
P Value
All 
(n = 32)
GOLD I 
(n = 12)
GOLD II 
(n = 13)
GOLD III/IV 
(n = 7)
Age (y) 70 6 11 74 6 7 75 6 8 74 6 8 73 6 6 .104
No. of male subjects 15 25 11 9 5 …
Body mass index (kg/m2) 30 6 4 26 6 3 26 6 3 27 6 3 26 6 4 ,.001
Smoking history (pack-years) 28 6 16 43 6 26 31 6 17 50 6 28 51 6 30 .012
FEV1* 103 6 19 73 6 27 101 6 14 64 6 10 39 6 7 ,.001
FEV1/FVC (%) 80 6 7 55 6 11 63 6 4 55 6 8 40 6 5 ,.001
Total lung capacity* 96 6 13 110 6 16† 103 6 34‡ 106 6 17 115 6 20 ,.001
Inspiratory capacity* 103 6 23 91 6 27 100 6 23 94 6 32 70 6 10 .078
Residual volume* 100 6 21 140 6 39 123 6 16 134 6 33 180 6 53 ,.001
DLCO* 89 6 18
§ 68 6 23† 73 6 29‡ 66 6 24 51 6 15 ,.001
Note.—Unless otherwise indicated, data are mean plus or minus standard deviation. P values were determined by analysis of variance with Tukey correction.
* Percent of predicted value.
† n = 31.
‡ n = 11.
§ n = 25.
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those with GOLD I disease (0.34 cm2/s 
6 0.03, P = .2).
Relationships for MR Imaging and PRM 
Measurements
Tables 3 and 4 show the Holm-Bonfer-
roni-corrected Pearson correlations and 
multivariate regression model results 
for CT-derived PRM gas trapping and 
(GOLD I, 31% 6 11, P , .001). PRM 
emphysema was significantly different 
between those with GOLD I and GOLD 
III/IV disease (P = .03). ADC values 
were significantly different between 
healthy ex-smokers (0.29 cm2/s 6 0.08) 
and those with GOLD II (0.36 cm2/s 6 
0.06, P = .02) and GOLD III/IV (0.41 6 
0.05 cm2/s, P , .001) disease, but not 
(gas trapping, 13% 6 10; emphysema, 
0.5% 6 0.5) and those with moderate 
(GOLD II: gas trapping, 27 6 14%, P = 
.003; emphysema, 8 6 11%, P = .003) 
to severe (GOLD III/IV: gas trapping, 
41 6 8%, P , .001; emphysema, 13 6 
12%, P , .001) COPD. PRM gas trap-
ping was significantly different between 
ex-smokers and those with mild COPD 
Figure 1
Figure 1: Ventilation and PRM in a 55-year-old man without COPD (FEV
1
, 83% of predicted value; FEV
1
/FVC, 77%; 
residual volume to total lung capacity ratio [RV/TLC], 45%), a 69-year-old man with GOLD I disease (FEV
1
, 89% of pre-
dicted value; FEV
1
/FVC, 69%; RV/TLC, 39%; DL
CO
, 67% of predicted value), an 84-year-old man with GOLD II disease 
(FEV
1
, 52% of predicted value; FEV
1
/FVC, 44%; RV/TLC, 62%; DL
CO
, 47% of predicted value), and a 67-year-old woman 
with GOLD III disease (FEV
1
, 33% of predicted value; FEV
1
/FVC, 39%; RV/TLC, 72%; DL
CO
, 28% of predicted value). First 
row: 3He MR images coregistered with 1H MR images (grayscale) show static ventilation (blue areas). Second row: 
3He MR imaging ADC maps show that the ex-smokers with more advanced COPD (GOLD II/III disease) have elevated 
ADC values. Third row: CT attenuation masks show areas of less than 2950 HU (yellow areas). Fourth row: PRMs show 
areas of healthy tissue (green), gas trapping (yellow), and emphysema (red).
602 radiology.rsna.org n Radiology: Volume 279: Number 2—May 2016
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defects are present in the ex-smoker 
with severe airflow limitation.
To explore these relationships in 
more detail, we quantitatively eval-
uated the spatial overlap of PRM gas 
trapping and emphysema voxels with 
ADC and ventilation defects (Table 5, 
Fig 5). As shown in Figure 5, 3He 
ADC was significantly elevated in areas 
of PRM gas trapping compared with 
healthy tissue (P = .004 in a healthy ex-
smoker, P = .01 in patients with GOLD 
I and GOLD II disease, P = .03 in a pa-
tient with GOLD III/IV disease). Helium 
3 ADC values were also significantly 
greater in the regions of PRM emphy-
sema compared with regions of PRM 
gas trapping in patient with GOLD I 
disease (P = .03), but not in healthy 
ex-smokers or those with GOLD II, III, 
or IV disease. Table 5 shows that, in 
mild and moderate COPD, the MR im-
aging spatial overlap coefficient (SOC) 
for 3He ventilation defects with PRM 
gas trapping tissue (MR imaging SOC = 
36% 6 28 and MR imaging SOC = 34% 
6 28 in those with mild and moderate 
disease, respectively) was significantly 
greater than for PRM emphysema 
VDP, there was a negative bias for PRM 
gas trapping (29% 6 12; 95% confi-
dence interval: 232%,15%) and a pos-
itive bias for PRM emphysema (11% 6 
9; 95% confidence interval: 26%, 28%). 
Table 4 shows that, in the multivariate 
regression model that explains PRM gas 
trapping, FEV1/FVC (standardiced coef-
ficient [bS] = 20.69, P = .001) and wall 
area percent (bS = 20.22, P = .02) make 
significant contributions, whereas, for 
the PRM emphysema model, DLCO (bS = 
20.29, P = .03) and VDP (bS = 0.41, P = 
.001) were significant.
Spatial and Regional Relationships
Given the significant quantitative re-
lationships between MR imaging and 
PRM COPD measurements, we evalu-
ated the spatial correlations of ventila-
tion defects with PRM measurements. 
Qualitative examples are shown in 
Figure 4 for an ex-smoker with mild 
COPD and another with GOLD III 
COPD. The spatial relationship between 
ventilation defects and PRM gas trap-
ping is more obvious in the ex-smoker 
with mild disease, whereas colocaliza-
tion of PRM emphysema and ventilation 
emphysema measurements. In ex-smok-
ers with COPD only, PRM gas trapping 
was significantly related to FEV1/FVC (r 
= 20.58, P = .003), ADC (r = 0.53, P = 
.01), and VDP (r = 0.47, P = .03). PRM 
emphysema was significantly correlated 
with FEV1 (r = 20.43, P = .03), FEV1/
FVC (r = 20.52, P = .008), DLCO (r = 
20.69, P , .001), ADC (r = 0.69, P , 
.001), and VDP (r = 0.62, P , .001) in 
ex-smokers with COPD. Figure 3 shows 
linear regressions for PRM gas trapping 
and emphysema and shows that VDP 
was significantly correlated with PRM 
gas trapping (r = 0.58, P , .001) and 
PRM emphysema (r = 0.68, P , .001) 
in all subjects and in ex-smokers with 
COPD (gas trapping: r = 0.47, P = .03; 
emphysema: r = 0.62, P , .001), but 
not in healthy ex-smokers. ADC was 
also significantly correlated with PRM 
gas trapping (r = 0.55, P , .001) and 
PRM emphysema (r = 0.62, P , .001) 
in all subjects and in ex-smokers with 
COPD (gas trapping: r = 0.53, P = .01; 
emphysema: r = 0.69, P , .001), but 
not in healthy ex-smokers. Figure 3 also 
shows Bland-Altman plots for PRM gas 
trapping and emphysema. In relation to 
Table 2
Imaging Measurements
Measurement
Healthy 
Ex-Smokers 
(n = 26)
Ex-smokers with COPD
P Value
All 
(n = 32)
GOLD I 
(n = 12)
GOLD II 
(n = 13)
GOLD III/IV 
(n = 7)
CT
 RA950 (%) 2 6 1 10 6 9 6 6 4 10 6 10 15 6 12 ,.001
 RA856 (%) 14 6 10 37 6 18 34 6 13 35 6 20 53 6 16 ,.001
 6G wall area percent (%) 65 6 2 65 6 2 65 6 2 66 6 2 66 6 2 .882
3He MR imaging
 Ventilation (%) 92 6 4 20 6 13 88 6 6 80 6 11 63 6 9 ,.001
 VDP (%) 8 6 4* 12 6 4 12 6 6 20 6 11 37 6 9 ,.001
 ADC (cm2/sec) 0.29 6 0.08* 0.36 6 0.06† 0.34 6 0.03‡ 0.36 6 0.06§ 0.41 6 0.05 ,.001
PRM
 Healthy (%) 85 6 11 60 6 18 64 6 13 63 6 20 46 6 17 ,.001
 Gas trapping (%) 13 6 10 31 6 12 31 6 11 27 6 14 41 6 9 ,.001
 Emphysema (%) 0.5 6 0.5 7 6 10 3 6 3 8 6 11 13 6 12 .001
Note.—Data are mean plus or minus standard deviation. P values were determined by analysis of variance with Tukey correction. RA950 = relative area of the lung with attenuation values less than 
2950 HU at inspiration CT, RA856 = relative area of the lung with attenuation values less than 2856 HU at expiration CT, 6G = sixth-generation airway.
* n = 24.
† n = 30.
‡ n = 11.
§ n = 12.
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regions of 3He ventilation defects. In 
addition, in patients with severe COPD, 
MR imaging SOC for 3He ventilation 
defects with PRM gas trapping voxels 
(SOC = 62% 6 25) was significantly 
greater than that for PRM emphysema 
(SOC = 11% 6 20, P = .009). Hence, in 
patients with severe COPD, regions of 
In patients with severe COPD, the CT 
SOC for 3He ventilation defects with 
PRM emphysema (CT SOC = 64% 6 
30) was significantly greater than that 
for PRM gas trapping voxels (CT SOC 
= 36% 6 18; P = .01). Therefore, for 
patients with severe COPD, PRM em-
physema was mainly localized within 
voxels (mild: MR imaging SOC 1% 6 
2, P = .001, and MR imaging SOC = 7% 
6 15, P = .006, in those with mild and 
moderate disease, respectively). Thus, 
in patients with mild and moderate 
COPD, 3He ventilation defects showed 
a greater spatial relationship with PRM 
gas trapping versus emphysema voxels. 
Figure 2
Figure 2: 3He MR imaging ventilation and PRM measurements by COPD grade. A, Box plot shows 3He MR imaging VDP in 
ex-smokers without COPD (8% 6 4) and with GOLD I (11% 6 6), GOLD II (20% 6 11), and GOLD III/IV (37% 6 9) disease. 
There was a significant difference in VDP between ex-smokers without COPD and those with GOLD II disease (P , .001), 
ex-smokers without COPD and those with GOLD III/IV disease (P , .001), those with GOLD I and GOLD II disease (P = .04), 
those with GOLD II and GOLD III/IV disease (P , .001), and those with GOLD I and GOLD III/IV disease (P , .001). B, Box 
plot shows PRM-derived gas-trapping voxels in ex-smokers without COPD (13% 6 10) and ex-smokers with GOLD I (31% 
6 11), GOLD II (27% 6 14), and GOLD III/IV (41% 6 8) disease. There is a significant difference in PRM gas trapping 
between ex-smokers without COPD and those with GOLD I disease (P , .001), ex-smokers without COPD and those with 
GOLD II disease (P = .003), and ex-smokers without COPD and those with GOLD III/IV disease (P , .001). C, Box plot shows 
3He MR imaging ADC values in ex-smokers without COPD (0.29 cm2/s 6 0.08) and those with GOLD I (0.34 cm2/s 6 0.03), 
GOLD II (0.36 cm2/s 6 0.06), and GOLD III/IV (0.41 cm2/s 6 0.05) disease. There is a significant difference in ADC values 
between ex-smokers without COPD and those with GOLD II disease (P = .02), ex-smokers without COPD and those with 
GOLD III/IV disease (P , .001), and those with GOLD I and GOLD III/IV disease (P = .04). D, Box plot shows PRM-derived 
emphysema voxels in ex-smokers without COPD (0.5% 6 0.5) and those with GOLD I (3% 6 3), GOLD II (8% 6 11), and 
GOLD III/IV (13% 6 12) disease. There is a significant difference in PRM emphysema between ex-smokers without COPD 
and those with GOLD II disease (P = .009), ex-smokers without COPD and those with GOLD III/IV disease (P = .001), and 
those with GOLD I and GOLD III/IV disease (P = .03). Significant differences between subgroups (P , .05) were determined 
with analysis of variance and post hoc Tukey analysis. Error bars = standard deviation.
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Table 3
Pearson Correlations for PRM Gas Trapping and Emphysema Measurements
Variable
PRM Gas Trapping PRM Emphysema
Healthy  
Ex-Smokers* P Value
Ex-Smokers  
with COPD† P Value
Healthy  
Ex-Smokers* P Value
Ex-Smokers  
with COPD† P Value
FEV1
‡ 20.09 .9 20.29 .1 20.11 .9 20.43 .03
FEV1/FVC (%) 20.33 .6 20.58 .003 20.34 .6 20.52 .008
DLCO
‡ 20.06 .8 20.36 .09 20.21 .9 20.69 ,.001
ADC (cm2/sec) 0.08 .9 0.53 .01 0.30 .8 0.69 ,.001
6G (%) 20.16 .9 20.44 .07 20.22 .9 20.14 .4
VDP (%) 0.13 .9 0.47 .03 0.10 .7 0.62 ,.001
Note.—Unless otherwise indicated, data are Pearson correlation coefficients. P values were determined with Holm-Bonferroni correction. Data were adjusted for age, sex, height, weight, and smoking 
history. P = .15 indicates a significant difference. 6G = sixth-generation airway wall area percent.
* n = 26.
† n = 32.
‡ Percent of predicted value. 
Table 4
Multivariate Regressions for PRM Gas Trapping and Emphysema Measurements
Variable
PRM Gas Trapping PRM Emphysema
b
U
b
S
Partial R 2 P Value b
U
b
S
Partial R 2 P Value
FEV1* … … … … … … … …
FEV1/FVC (%) 20.65 20.69 0.53 .001 … … … …
DLCO* … … … … 20.10 20.29 0.10 .03
ADC (cm2/sec) … … … … … … … …
6G (%) 21.72 20.22 0.08 .02 … … … …
VDP (%) … … … … 0.29 0.41 0.20 .001
Note.—Unless otherwise indicated, data are Pearson correlation coefficients. P values were determined with Holm-Bonferroni correction. Data were adjusted for age, sex, height, weight, and smoking 
history. P = .15 indicates a significant difference. n = 58. 6G = sixth-generation airway, bU = unstandardized regression coefficient, bS = standardized regression coefficient.
* Percent of predicted value. 
3He ventilation defects mostly consisted 
of PRM gas trapping voxels, although 
there was a mixture of PRM gas trap-
ping and emphysema.
Discussion
We evaluated 58 ex-smokers in the 
first direct comparison of PRM and 
MR imaging measurements of COPD. 
We acquired inspiration and expira-
tion CT images and noble gas MR im-
ages within 1 hour and observed the 
following findings: (a) with increasing 
severity of airflow limitation, PRM gas 
trapping, PRM emphysema, ADC, and 
VDP measurements were significantly 
greater; (b) 3He ventilation and PRM 
measurements were correlated in 
COPD but not in healthy ex-smokers; 
(c) in a multivariate model that pre-
dicted PRM gas trapping, wall area 
percent and FEV1/FVC were signifi-
cant, whereas VDP and DLCO were sig-
nificant for PRM emphysema; and (d) 
3He ADC values were significantly ele-
vated in regions of PRM gas trapping, 
and there were quantitative and spatial 
correlations for both PRM gas trap-
ping and emphysema with 3He ventila-
tion defects that differed according to 
COPD severity.
PRMs are used to classify lung tis-
sue on the basis of the presence of pul-
monary air, either as a consequence of 
emphysema and gas trapping from air-
ways disease and/or emphysema (9). 
We were curious about the potential 
relationships between PRM and MR im-
aging phenotypes of COPD, especially 
because both ventilation defects and 
PRM gas trapping have been suggested 
as biomarkers of small airways disease. 
First, we observed that, with increasing 
severity of airflow limitation, PRM gas 
trapping, PRM emphysema, ADC, and 
VDP measurements were significantly 
greater. We also noted that 3He VDP 
and PRM measurements were corre-
lated in ex-smokers with COPD but not 
in ex-smokers with normal pulmonary 
function. This finding might be expected 
because correlations in ex-smokers with 
mainly normal pulmonary function are 
statistically difficult to ascertain in small 
sample sizes, since the range of values 
for normal lung function is small (31). It 
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PRM functional small-airway disease 
that leads to gas trapping may be seen 
as enlarged airs paces, which is re-
flected by elevated ADC values. This 
is one of the first studies to spatially 
compare 3He ADC to gas-trapping 
measurements. This novel finding is in 
agreement with other studies that dem-
onstrated gravitational and lung volume 
effects on pulmonary ADC values (39–
39). This also suggests that abnormally 
elevated ADC values may not always re-
flect emphysematous abnormalities in 
patients with COPD. There were also 
spatial correlations in patients with 
mild and moderate COPD, in whom 
3He MR imaging ventilation defects 
were spatially related to PRM gas trap-
ping. In contrast, in the small group of 
seven patients with severe COPD, MR 
imaging ventilation defects were spa-
tially related to both PRM gas trapping 
and emphysema, which were identified 
with CT and MR imaging SOC. The ra-
tionale for performing SOC analysis in 
(35). However, we note that, while 
the significant contribution of DLCO 
to PRM emphysema is also consistent 
with a large body of previous work, the 
contribution of PRM emphysema to 
ventilation defects is a novel and some-
what surprising result (36). Strong 
hints that ventilation defects may stem 
from emphysematous bullae were pre-
viously reported in patients with ad-
vanced or severe COPD and numerous 
exacerbations that required hospitali-
zation (22). Together, this information 
suggests a role for pulmonary imaging 
to phenotype COPD beyond FEV1 to 
help guide therapy and change exacer-
bations and other outcomes.
These quantitative associations 
and some obvious qualitative regional 
relationships led to our exploration of 
potential spatial correlations. Notably 
(and unexpectedly), we observed that 
3He ADC values were significantly ele-
vated in regions of PRM gas trapping. 
This surprising result suggested that 
is also worth noting that, in this study, 
CT emphysema measurements for 
healthy ex-smokers were in agreement 
with previously reported values for 
healthy subjects (7,32). Importantly, CT 
may not be adequately sensitive to very 
mild or subclinical parenchymal and ob-
structive disease; this may also partially 
explain the negligible VDP and PRM cor-
relations in healthy ex-smokers (33).
In addition to these bilateral rela-
tionships, multivariate modeling iden-
tified the parameters that significantly 
added to the model for PRM gas trap-
ping (wall area percent and FEV1/FVC) 
and PRM emphysema (VDP and DLCO). 
The PRM gas trapping model is intui-
tive and was developed on the basis of 
our previous knowledge of the role of 
airway wall morphologic characteris-
tics in functional small airways disease 
(34). This finding is also consistent 
with the major pulmonary imaging and 
clinical phenotypes that were recently 
summarized by the Fleischner Society 
Figure 3
Figure 3: Relationships between 3He MR imaging VDP and ADC with PRM-derived gas-trapping and PRM emphysema voxels. A, Scatter plot shows linear 
regression for 3He MR imaging VDP with PRM in all subjects (gas-trapping voxels: r = 0.58, r 2 = 0.34, P , .001, y = 0.73x 2 12.88; emphysema voxels: r = 
0.68, r 2 = 0.47, P , .001, y = 0.47x 2 2.78), ex-smokers without COPD (gas-trapping voxels: r = 0.13, r 2 = 0.02, P = .9, y = 0.35x + 10.92; emphysema 
voxels: r = 0.10, r 2 = 0.009, P = .7, y = 0.01x + 0.39), and ex-smokers with COPD (gas-trapping voxels: r = 0.47, r 2 = 0.23, P = .03, y = 0.46x + 22.12; 
emphysema voxels: r = 0.62, r 2 = 0.38, P , .001, y = 0.46x 2 2.22). B, Scatter plot shows linear regression for 3He MR imaging ADC with PRM in all subjects 
(gas-trapping voxels: r = 0.55, r 2 = 0.30, P , .001, y = 122x 2 17; emphysema voxels: r = 0.62, r 2 = 0.39, P , .001, y = 77x 2 22), ex-smokers without 
COPD (gas-trapping voxels: r = 0.08, r 2 = 0.006, P = .9, y = 14x + 10; emphysema voxels: r = 0.30, r 2 = 0.09, P = .8, y = 2.5x 2 0.3), and ex-smokers with 
COPD (gas-trapping voxels: r = 0.53, r 2 = 0.28, P = .01, y = 119x 2 12; emphysema voxels: r = 0.69, r 2 = 0.48, P , .001, y = 121x 2 37). C, Bland-Altman 
plot shows analysis of agreement for 3He MR imaging VDP and PRM in all subjects (gas-trapping voxels: bias = 29% 6 12, lower limit = 232%, upper limit = 
15%; emphysema voxels: bias = 11% 6 9, lower limit = 26%, upper limit = 28%), ex-smokers without COPD (gas-trapping voxels: bias = 26% 6 10, lower 
limit = 226%, upper limit = 15%; emphysema voxels: bias = 8% 6 4, lower limit = 1%, upper limit = 15%), and ex-smokers with COPD (gas-trapping voxels: 
bias = 211% 6 13, lower limit = 236%, upper limit = 14%; emphysema voxels: bias = 13% 6 10, lower limit = 27%, upper limit = 33%). Dotted lines = 
95% confidence intervals.
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overlap analysis in both directions be-
cause the results showed that, in severe 
COPD, PRM emphysema voxels were 
mainly occupied by ventilation defect 
voxels. In contrast, ventilation defect 
voxels were mainly occupied by PRM 
gas-trapping voxels. This means that 
both PRM emphysema and gas-trap-
ping voxels are spatially coincident with 
ventilation defects. This exciting result 
provides, for the first time, a deeper 
understanding of the source of ventila-
tion defects and gas trapping in COPD. 
We think that these findings underscore 
the importance of phenotyping COPD 
cases with quantitative imaging. Future 
work should aim to determine the spa-
tial relationships between continuous 
pixel-wise data and PRM, as this may 
provide a better understanding of these 
relationships.
Numerous studies have used paired 
inspiratory and expiratory lung CT 
images to provide COPD phenotypes 
(42–44). In patients with COPD, gas 
trapping is influenced by both em-
physema and small-airways disease, 
differentiation of which is attempted 
with PRM (43,45). In addition, severe 
small-airways disease sometimes ap-
pears at CT as emphysema, making it 
challenging to delineate between the 
two phenotypes. Regardless, in this 
study, we determined the different re-
lationships between MR imaging and 
CT phenotypes of COPD cases across 
GOLD grades of severity. We think 
that these results underscore the need 
to adopt multimodality approaches to 
deeply phenotype COPD cases so that 
the independent contributions of em-
physema and airways disease may be 
ascertained, which may help optimize 
COPD therapy and improve outcomes.
In summary, in all ex-smokers, 
ventilation defects and ADC values 
were correlated with PRM gas trap-
ping and emphysema measurements. 
In a subset of ex-smokers with mild to 
moderate COPD, ventilation defects 
were quantitatively and spatially re-
lated to PRM gas trapping, whereas in 
severe COPD, there were spatial and 
quantitative relationships for ventila-
tion defects with both PRM gas trap-
ping and emphysema.
methods, this was not a result of asym-
metry between registering from the fixed 
to the moving image because we per-
formed registration in a symmetric man-
ner to mitigate this potential bias (40,41). 
It was important to perform the spatial 
both directions was the need to eval-
uate the overlap of 3He defects within 
PRM regions (CT SOC) and the overlap 
of PRM voxels within 3He defects (MR 
imaging SOC). While the quantitative re-
sults showed differences between the two 
Figure 4
Figure 4: Spatial relationship of 3He MR imaging ventilation defects with PRM gas trapping and emphy-
sema. 3He MR images coregistered with 1H MR imaging and CT obtained in, A, a 69-year-old man with mild 
COPD (GOLD I; FEV
1
, 89% of predicted value; FEV
1
/FVC, 69%; RV/TLC, 39 FEV
1
%, DL
CO
, 67% of predicted 
value) and, B, a 78-year-old man with severe COPD (GOLD III; 47% of predicted value; FEV
1
/FVC, 37%; 
RV/TLC, 50%; DL
CO
, 57% of predicted value) show 3He MR imaging ventilation (blue), PRM healthy tissue 
(green), PRM gas trapping (yellow), and PRM emphysema (red), as well as the spatial relationship between 
ventilation defects with regions of PRM gas trapping and emphysema (arrows).
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Table 5
Quantitative Spatial Relationships for 3He MR imaging Ventilation Defects with CT PRM Voxels
Characteristic
Healthy Ex-Smokers  
(n = 26)
 Ex-Smokers with COPD 
P ValueAll (n = 32) GOLD I (n = 12) GOLD II (n = 13) GOLD III/IV (n = 7)
Spatial Overlap Coefficient Normalized with CT Voxels
Gas trapping to VDP (%) 3 6 12 15 6 16 4 6 4 13 6 13 36 6 18 ,.001
Emphysema to VDP (%) 0 6 0 22 6 32 3 6 9 16 6 27 64 6 30 ,.001
Significant difference* 0.2 0.06 0.5 0.5 0.01 …
Spatial Overlap Coefficient Normalized with MR Imaging Voxels
VDP to gas trapping (%) 3 6 8 41 6 29 36 6 28 34 6 28 62 6 25 ,.001
VDP to emphysema (%) 0 6 0 6 6 14 1 6 2 7 6 15 11 6 20 .04
Significant difference* 0.09 ,0.001 0.001 0.006 0.009 …
Note.—Unless otherwise indicated, data are mean plus or minus standard deviation. P values were determined with analysis of variance and Tukey correction; P , .05 indicates a significant difference.
*Significant difference was measured with paired t test for spatial overlap coefficients of MR imaging ventilation defects with PRM gas trapping and emphysema.
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